Skip to main content

Clinical Trials Using Abiraterone Acetate

Review the clinical trials studying abiraterone acetate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 233 locations
Targeted Treatment for Metastatic Prostate Cancer, PREDICT Trial
Status: Active
Location: 68 locations
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Status: Active
Location: 17 locations
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: 13 locations
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer, TIP Trial
Status: Active
Location: 10 locations
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Status: Active
Location: 21 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Status: Active
Location: 8 locations
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Status: Active
Location: 8 locations
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Status: Active
Location: 7 locations
Talazoparib with Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer, TRIPLE-PRO Trial
Status: Active
Location: 5 locations
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Status: Active
Location: 6 locations
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Active
Location: 6 locations
Evaluation of Response to Abiraterone Acetate, Prednisone, and Androgen Deprivation Therapy by Race or Ethnicity in Patients with Metastatic Prostate Cancer
Status: Active
Location: 3 locations
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Status: Active
Location: 6 locations
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Status: Active
Location: 2 locations
Androgen Ablation Therapy with or without Niraparib after Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Status: Active
Location: 2 locations
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Status: Active
Location: 2 locations
Leuprolide and Abiraterone Acetate (AA) versus Relugolix and AA for the Treatment of Non-Metastatic Recurrent Prostate Cancer, the REVELUTION-2 Trial
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
An Investigational Scan (HP 13C MRI) for Assessing Response to Treatment with Abiraterone Acetate and Prednisone prior to Surgery in Patients with High-Risk Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Adaptive Androgen Deprivation Therapy and Docetaxel for the Treatment of Metastatic Castration Sensitive Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Niraparib and Abiraterone Acetate plus Prednisone for the Treatment of Hispanic/Latino and Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer with Deleterious Homologous Recombination Repair Alterations, HARMONY Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants with Metastatic Castration Resistant Prostate Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas